AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27179823 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal Exposure with Withdrawal Regulation Training (WT)
Number of subjects: 80
Study 27179823 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Control (RC)
Number of subjects: 80
Study 25278714 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic imaging-assisted colonoscopy (MIC)
Number of subjects: 253
Study 25278714 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 253
Study 24368060 — intervention group
Group type: EXPERIMENTAL
Intervention: early modified IPS intervention in addition to treatment-as-usual
Number of subjects: 324
Study 24368060 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual alone
Number of subjects: 324
Study 21329267 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based stimulation programme on early literacy skills, duration: 8 weeks
Number of subjects: 0
Study 21329267 — intervention group
Group type: COMPARATOR
Intervention: Control groups (English first language (L1) and ELL control groups)
Number of subjects: 0
Study 17967917 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-PQ (piperaquine phosphate at 20 mg/kg/day for 3 days)
Number of subjects: 42
Study 17967917 — intervention group
Group type: COMPARATOR
Intervention: CQ-SP (chloroquine at 10 mg base/kg/day for 3 days with a single dose of sulfadoxine-pyrimethamine)
Number of subjects: 42
Study 17967917 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-PQ (piperaquine)
Number of subjects: 42
Study 17967917 — intervention group
Group type: COMPARATOR
Intervention: CQ-SP (chloroquine)
Number of subjects: 42
Study 17967917 — intervention group
Group type: COMPARATOR
Intervention: DECQ (active metabolite of chloroquine)
Number of subjects: 42
Study 15827587 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme
Number of subjects: 144
Study 15827587 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 14655921 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 27
Study 14655921 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Bilevel (NBL) therapy
Number of subjects: 27
Study 10394523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation (clomiphene citrate plus human menopausal gonadotropin)
Number of subjects: 834
Study 10394523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort stimulation (gonadotropin releasing hormone agonist plus hMG or FSH)
Number of subjects: 834
Study 10394523 — intervention group
Group type: EXPERIMENTAL
Intervention: Long downregulation protocol
Number of subjects: 834
Study 8892490 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite system using 10 in- and post-hospital variables
Number of subjects: 2830
Study 8892490 — intervention group
Group type: COMPARATOR
Intervention: In-hospital data only system
Number of subjects: 2830
Study 2049748 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC plus RT (procarbazine, vincristine, and lomustine with whole-brain irradiation)
Number of subjects: 171
Study 2049748 — intervention group
Group type: COMPARATOR
Intervention: PVC alone (procarbazine, vincristine, and lomustine without whole-brain irradiation)
Number of subjects: 171
Study 2049748 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC plus RT
Number of subjects: 171
Study 2049748 — intervention group
Group type: COMPARATOR
Intervention: PVC alone
Number of subjects: 171
Study 2049748 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 171
Study 2049748 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, Karnofsky index, areas of Grade 2, and absence of extensive necrosis in the tumor
Number of subjects: 171
Study 6429406 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with EAA (2.3 g of nitrogen per day)
Number of subjects: 11
Study 6429406 — intervention group
Group type: COMPARATOR
Intervention: TPN with ENAA (11.3 g of nitrogen per day)
Number of subjects: 11
Study 31577219 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic supracervical hysterectomy (LASH)
Number of subjects: 660
Study 31577219 — intervention group
Group type: COMPARATOR
Intervention: Second-generation endometrial ablation (EA)
Number of subjects: 660
Study 29364338 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (Whiteness HP Maxx 35% ‐ FGM)
Number of subjects: 60
Study 29364338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (GIII and GIV)
Number of subjects: 60
Study 26833396 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exposure therapy (n = 50)
Number of subjects: 100
Study 26833396 — intervention group
Group type: COMPARATOR
Intervention: Traditional OST (n = 50)
Number of subjects: 100
Study 24065327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptococcal antigen (CRAG) lateral flow assay (LFA)
Number of subjects: 0
Study 24065327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment LFA titers
Number of subjects: 0
Study 22790961 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 434
Study 22790961 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 434
Study 19832909 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-coated toothbrush filaments
Number of subjects: 64
Study 19832909 — intervention group
Group type: COMPARATOR
Intervention: Control toothbrushes
Number of subjects: 64
Study 18046926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial premixed insulin analogues (70% or 75% basal and 30% or 25% rapid-acting insulin analogue)
Number of subjects: 0
Study 18046926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial premixed insulin analogues (50% basal and 50% rapid-acting insulin analogue)
Number of subjects: 0
Study 18046926 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin analogues
Number of subjects: 0
Study 15031136 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (three 45-min bouts of cycle ergometry each night)
Number of subjects: 18
Study 15031136 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control condition
Number of subjects: 18
Study 11921591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 15
Study 11921591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 15
Study 11921591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 15
Study 11921591 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (washout period)
Number of subjects: 15
Study 11921591 — intervention group
Group type: EXPERIMENTAL
Intervention: All NSAIDs
Number of subjects: 15
Study 9778324 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy followed by coronary stenting
Number of subjects: 71
Study 7834869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis patients
Number of subjects: 29
Study 7834869 — intervention group
Group type: COMPARATOR
Intervention: Outwardly healthy Sowetans
Number of subjects: 29
Study 7834869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sowetan patients vs Manchester controls
Number of subjects: 29
Study 3047900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoregulatory agents
Number of subjects: 8
Study 31651545 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue ART (CTART)
Number of subjects: 939
Study 31651545 — intervention group
Group type: COMPARATOR
Intervention: Discontinue ART (DCART)
Number of subjects: 939
Study 30914496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas mask with cartridge A (3.5 cm H2O inspiratory resistance)
Number of subjects: 8
Study 30914496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas mask with cartridge B (2.2 cm H2O inspiratory resistance)
Number of subjects: 8
Study 30914496 — intervention group
Group type: COMPARATOR
Intervention: Baseline without gas mask
Number of subjects: 8
Study 28355362 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide (White Class with calcium - FGM)
Number of subjects: 30
Study 28355362 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (White Class with calcium - FGM)
Number of subjects: 30
Study 28355362 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide (Oral B 3D White - Oral-B)
Number of subjects: 30
Study 28355362 — intervention group
Group type: COMPARATOR
Intervention: Control group - placebo
Number of subjects: 30
Study 26632500 — intervention group
Group type: EXPERIMENTAL
Intervention: AC TightRope fixation (TR group)
Number of subjects: 68
Study 26632500 — intervention group
Group type: COMPARATOR
Intervention: Bosworth screw fixation (BS group)
Number of subjects: 68
Study 23698019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 injection of lidocaine (0.5%)
Number of subjects: 108
Study 23698019 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 injections of lidocaine (0.5%)
Number of subjects: 108
Study 23698019 — intervention group
Group type: COMPARATOR
Intervention: 1 injection of saline (NaCl 0.9%)
Number of subjects: 108
Study 23698019 — intervention group
Group type: COMPARATOR
Intervention: 5 injections of saline (NaCl 0.9%)
Number of subjects: 108
Study 20518813 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets
Number of subjects: 77
Study 20518813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device
Number of subjects: 77
Study 20518813 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets and ultrasonic device
Number of subjects: 77
Study 20518813 — intervention group
Group type: COMPARATOR
Intervention: Brushing with water (control)
Number of subjects: 77
Study 18348774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (single dose of 50 mg/kg)
Number of subjects: 166
Study 18348774 — intervention group
Group type: COMPARATOR
Intervention: Nitazoxanide (7.5 mg/kg twice a day for 3 days)
Number of subjects: 166
Study 15940095 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention for alcohol plus a booster (1 ED session plus booster session)
Number of subjects: 539
Study 15940095 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention for alcohol plus a booster (n=34 motor vehicle crash patients)
Number of subjects: 539
Study 15940095 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=46 motor vehicle crash patients)
Number of subjects: 539
Study 15940095 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (1 ED session)
Number of subjects: 539
Study 15940095 — intervention group
Group type: COMPARATOR
Intervention: Standard care (non-motor vehicle crash patients)
Number of subjects: 539
Study 11954681 — intervention group
Group type: EXPERIMENTAL
Intervention: Most important interventions for primary problems
Number of subjects: 211
Study 11954681 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions including the most important and adjunctive ones
Number of subjects: 211
Study 11954681 — intervention group
Group type: EXPERIMENTAL
Intervention: Most important interventions for secondary problems
Number of subjects: 211
Study 9649967 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 5
Study 9649967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum smoking
Number of subjects: 5
Study 9649967 — intervention group
Group type: COMPARATOR
Intervention: Abstinence
Number of subjects: 5
Study 7650235 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol nasal spray (1 mg)
Number of subjects: 24
Study 7650235 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol nasal spray plus sumatriptan (1 mg butorphanol + 6 mg SC sumatriptan)
Number of subjects: 24
Study 7650235 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol nasal spray
Number of subjects: 24
Study 2654406 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 75
Study 2654406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 410176 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrangin
Number of subjects: 31
Study 410176 — intervention group
Group type: EXPERIMENTAL
Intervention: ergocomb
Number of subjects: 31
Study 410176 — intervention group
Group type: EXPERIMENTAL
Intervention: euphyllin
Number of subjects: 31
Study 410176 — intervention group
Group type: EXPERIMENTAL
Intervention: rocornal
Number of subjects: 31
Study 410176 — intervention group
Group type: COMPARATOR
Intervention: no additional therapy
Number of subjects: 31
Study 30776911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary service needs (met and unmet)
Number of subjects: 348
Study 30776911 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric health and substance use issues (depression, anxiety, drug use)
Number of subjects: 348
Study 30776911 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 348
Study 30776911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting a specific individual need (met or unmet)
Number of subjects: 348
Study 28668399 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity statin therapy (atorvastatin 80mg/day)
Number of subjects: 130
Study 28668399 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity statin therapy (atorvastatin 20mg/day)
Number of subjects: 130
Study 25375664 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of patent foramen ovale (PFO)
Number of subjects: 57
Study 23480523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led ART
Number of subjects: 11882
Study 23480523 — intervention group
Group type: COMPARATOR
Intervention: Doctor-led ART
Number of subjects: 11882
Study 21665007 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sertraline plus 2 g/day omega‐3 fatty acids
Number of subjects: 122
Study 21665007 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of sertraline plus 2 g/day corn oil placebo capsules
Number of subjects: 122
Study 19426182 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanon barrier (test: T)
Number of subjects: 15
Study 19426182 — intervention group
Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate barrier (control: C)
Number of subjects: 15
Study 16717207 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 61
Study 16717207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15707254 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Techniques (RT)
Number of subjects: 36
Study 15707254 — intervention group
Group type: COMPARATOR
Intervention: Music Comparison Condition
Number of subjects: 36
Study 9159313 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine ointment
Number of subjects: 120
Study 9159313 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 120
Study 8422085 — intervention group
Group type: EXPERIMENTAL
Intervention: l-deprenyl (5 mg b.i.d.)
Number of subjects: 10
Study 8422085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 3655855 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CAFVP with MER)
Number of subjects: 395
Study 3655855 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CMF, CAF, CAFVP)
Number of subjects: 395
Study 3655855 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (overall)
Number of subjects: 395
Study 31987106 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutin with vitamin C (group A)
Number of subjects: 53
Study 31987106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C alone (group B)
Number of subjects: 53
Study 31987106 — intervention group
Group type: COMPARATOR
Intervention: Antidiabetic treatment only (group C)
Number of subjects: 53
Study 29430796 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (DMAb)
Number of subjects: 7808
Study 29430796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study 27102821 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble RSV fusion protein (sF) with 2.5μg glucopyranosyl lipid A (GLA) adjuvant
Number of subjects: 24
Study 27102821 — intervention group
Group type: COMPARATOR
Intervention: Soluble RSV fusion protein (sF) without adjuvant
Number of subjects: 24
Study 27102821 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble RSV fusion protein (sF) with GLA adjuvant at highest dosage level
Number of subjects: 24
Study 24441153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 44
Study 21424341 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 540
Study 20735858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution plus Saccharomyces boulardii
Number of subjects: 64
Study 20735858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution plus a compound containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii
Number of subjects: 64
Study 20735858 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration therapy plus placebo
Number of subjects: 64
Study 18474338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (2 mug/kg bolus; 0.01 mug/kg/min for 48 hours)
Number of subjects: 72
Study 18474338 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without nesiritide
Number of subjects: 72
Study 15957695 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (RG; n=20)
Number of subjects: 40
Study 15957695 — intervention group
Group type: COMPARATOR
Intervention: Saline (CG; n=20)
Number of subjects: 40
Study 12401625 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative 0.5% bupivacaine
Number of subjects: 0
Study 12401625 — intervention group
Group type: COMPARATOR
Intervention: Preoperative 2% lidocaine
Number of subjects: 0
Study 12401625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preoperative 2% lidocaine and postoperative 0.5% bupivacaine
Number of subjects: 0
Study 12401625 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study 10457394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) filtration daily over five days (group A)
Number of subjects: 10
Study 10457394 — intervention group
Group type: COMPARATOR
Intervention: Riluzole treatment only (group B)
Number of subjects: 10
Study 7573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 666
Study 7573786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 666
Study 7573786 — intervention group
Group type: COMPARATOR
Intervention: Malnutrition
Number of subjects: 666
Study 2104077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g sucralfate daily at bedtime
Number of subjects: 77
Study 2104077 — intervention group
Group type: COMPARATOR
Intervention: 1 g sucralfate four times daily (q.d.s.)
Number of subjects: 77
Study 350500 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen twice daily
Number of subjects: 40
Study 350500 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 40
Study 30964971 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare powered toothbrush (PTB)
Number of subjects: 148
Study 30964971 — intervention group
Group type: COMPARATOR
Intervention: American Dental Association (ADA) reference manual toothbrush (MTB)
Number of subjects: 148
Study 30964971 — intervention group
Group type: EXPERIMENTAL
Intervention: PTB
Number of subjects: 148
Study 30964971 — intervention group
Group type: COMPARATOR
Intervention: MTB
Number of subjects: 148
Study 27926975 — intervention group
Group type: EXPERIMENTAL
Intervention: LGA
Number of subjects: 50734
Study 27926975 — intervention group
Group type: COMPARATOR
Intervention: AGA
Number of subjects: 50734
Study 26040334 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access route
Number of subjects: 1857
Study 26040334 — intervention group
Group type: COMPARATOR
Intervention: Femoral access route
Number of subjects: 1857
Study 23566568 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial retinaculum plasty (MRP)
Number of subjects: 70
Study 23566568 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction (MPFLR)
Number of subjects: 70
Study 23566568 — intervention group
Group type: COMPARATOR
Intervention: Both MRP and MPFLR
Number of subjects: 70
Study 21616771 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (H-CHO; 60% of daily caloric intake)
Number of subjects: 16
Study 21616771 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate (L-CHO; 30% of daily caloric intake)
Number of subjects: 16
Study 19768691 — intervention group
Group type: EXPERIMENTAL
Intervention: Test treatment
Number of subjects: 0
Study 19768691 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 0
Study 19768691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16968916 — intervention group
Group type: EXPERIMENTAL
Intervention: Malarone (250 mg atovaquone plus 100 mg proguanil hydrochloride) daily from 1 day before entering the endemic area to 7 days after leaving the endemic area
Number of subjects: 180
Study 16968916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 16968916 — intervention group
Group type: EXPERIMENTAL
Intervention: Malarone
Number of subjects: 180
Study 15226514 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 70
Study 15226514 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment continued for 2 years
Number of subjects: 70
Study 15226514 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab infusions every 8 weeks
Number of subjects: 70
Study 15226514 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term model for infliximab treatment
Number of subjects: 70
Study 15226514 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 70
Study 11743484 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate and 61% ethyl alcohol (CHG/ethanol)
Number of subjects: 137
Study 11743484 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate (CHG)
Number of subjects: 137
Study 11743484 — intervention group
Group type: COMPARATOR
Intervention: 61% ethyl alcohol (control)
Number of subjects: 137
Study 11195315 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal OA in females
Number of subjects: 60
Study 11195315 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal OA in males
Number of subjects: 60